-
To provide you with critical information on the updated regulations from the Centers for Medicare and Medicaid Services, Thomson American Health Consultants offers "New EMTALA Regulations: Are They Too Good to be True?" an audio conference on Tuesday, Oct. 21, from 2:30-3:30 p.m., ET.
-
Before Tony Dorsey, an outreach worker with FACT in Las Vegas was infected with HIV through a needlestick injury, the possibility that his job as a phlebotomist could place him at risk never once occurred to him.
-
Investigators studying genotypes of 64,000 clinical samples submitted for genotyping to Virco based in Mechelen, Belgium, have found that HIV-1 drug resistance remains extensive, but that trends have shifted in recent years.
-
The $15 billion pledged by President Bush to fund an international HIV/AIDS treatment and prevention initiative has evaporated as quickly as a magicians rabbit out of the hat, international AIDS activists charge.
-
-
Community-based organizations (CBOs) and other groups representing minorities infected with HIV spent the early part of the fall meeting with national legislators and others to discuss keeping AIDS on the governments top agenda.
-
The most recent HIV/AIDS statistics from the Centers for Disease Control and Prevention (CDC) show that HIV is the leading cause of death for African-Americans, ages 25-44, in the United States and the third leading cause of death for both African-Americans and Latinos in the 35-44 age group.
-
Several studies presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) have shown how HIV patients who are co-infected with hepatitis C are at greater risk for medical complications, including diabetes.
-
Guidelines released this year from the U.S. Department of Health and Human Services (DHHS) and the International AIDS Society-USA2 (IAS) recommend resistance testing for all recently infected patients beginning treatment.
-
Researchers and AIDS activists who have witnessed AIDSs destructive path across the world have nearly two decades of observations and data to show how the epidemic can be halted in countries where it begins primarily as an IDU (injection drug use/injection drug user) transmission problem.
